NCT07124351
Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™)
At risk: Primary completion moved at least 12 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Aug 2026 to Aug 31, 2027
- Eligibility criteria expanded, about 11 words
- Study completion pushed from Sep 2026 to Sep 30, 2027
- Notable Phase: Phase 1 to Phase 4
- Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Aug 2025 to Sep 5, 2025
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Feasibility of CYTALUX™ (pafolacianine) with near-infrared (NIR) fluorescent imaging
Timeframe: 12 months
Secondary (1)
Number of Lesions
Arms and interventions
CYTALUX™ (pafolacianine)Experimental
Enrolled subjects will be dosed with 0.025 mg/kg CYTALUX™ (pafolacianine) injection intravenously, with the hour-long infusion completing from 1 hour to up to 24 hours prior to imaging for the planned surgery.
Drugs: CYTALUX™ (pafolacianine)
Sites
1 site in 1 country
- Cedars-Sinai Medical CenterLos Angeles, California, United States